Introduction
Human papillomavirus (HPV) is now considered as a causative agent of carcinoma of the uterine cervix. Human papillomaviruses (HPV) constitute a group of viruses associated with benign and malignant lesions of cutaneous and mucosal tissue. Presently, more than 100 different HPV genotypes have been identified, of which approximately 40 have been detected in the anogenital area. Genital human papillomaviruses are classified into low-risk and high-risk. The low-risk HPVs are associated with genital warts and lesions, as for the high-risk they are commonly associated with highgrade squamous intraepithelial lesions and cervical cancer. Cervical cancer is one of the most frequent causes of death from cancer in women worldwide. However due to cervical screening programs that risk has been reduced (4, 8, 9) . Currently, several main approaches are used to screen clinical specimens for the presence of HPV -PCR with consensus primers that amplify a region of the major viral capsid L1 gene that is highly conserved among anogenital HPVs, DNA hybridization which detects the presence of either low-risk or high-risk HPVs, by formation of DNA-DNA hybrids and realtime PCR using Taqman probes to detect and quantitate HPV types, molecular beacon-labeled primers (3, 4, 9, 10) . In this research we used Roche's LINEAR ARRAY HPV Genotyping Test (CE-IVD) (2, 6) . This method combines multiplex PCR with 40 pairs of primers and DNA hybridization. The products from the PCR are used to hybridize with nylon strips which contain immobilized DNAs of 38 types and subtypes of HPV genotypes. The cervical smears were collected from Bulgarian patients with condylata acuminate lesions, in three hospitals in Sofia -University Hospital of Obstetrics and Gynaecology "Maichin Dom", "Tokuda" Hospital and the "National Institute of Oncology and Hematology". 72 °c Indefinitely After the amplification process, 100 µl of denaturation solution (1.6% Sodium hydroxide, EDTA, Thymol blue) was added to each vial.
DETECTION AND GENOTYPING OF HUMAN PAPILLOMAVIRUSES IN BULGARIAN PATIENTS FOR THE PERIOD OF 2009-2010

papillomavirus (HPV) types have been identified. Genital human papillomaviruses are classified into low-risk and high-risk. The low-risk HPVs are associated with genital warts and lesions. Persistent infection with a subset of about 13 so-called "high-risk" sexually transmitted HPVs may lead to the development of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), penile intraepithelial neoplasia (PIN), and/or anal intraepithelial neoplasia (AIN). These are precancerous lesions and can progress to invasive cancer. HPV infection is a necessary factor in the development of nearly all cases of cervical cancer. The main methods in HPV diagnosis are molecular methods. In this research we used Roche's LINEAR ARRAY HPV Genotyping Test (CE-IVD). This method combines multiplex PCR with 40 pairs of primers and DNA hybridization. The products from the PCR are used to hybridize with nylon strips which contain immobilized DNAs of 38 types and subtypes of HPV genotypes. The cervical smears were collected from Bulgarian patients with condylata acuminate lesions, in three hospitals
LINEAR ARRAY detection
During the detection procedures we used several buffers (Hybridization Buffer, Ambient Wash Buffer, Stringent Buffer, Citrate buffer, Conjugate buffer) to carry out the experiment. Working Hybridization Buffer was prepared just before detection procedures as follows: 100 ml of SSPE (Sodium phosphate solution, Sodium chloride, EDTA, 1% ProClin 150) were added to 388 ml deionized water. After that 12.5 ml of SDS were added and mixed well. The Working Ambient Wash Buffer was prepared from 133 ml of SSPE, 2520 ml deionized water and 13.3 ml of SDS which were mixed well. Working citrate Buffer was prepared as follows: 25 ml CIT (Citrate Concentrate) and 475 ml deionized water. The Working conjugate Buffer was prepared using the Working Ambient Wash Buffer -5 ml to for each strip being tested to which we added 15 µl SA-HRP (Streptavidin-Horseradish Peroxidase conjugate, ACES buffer, Sodium chloride, 1% Proclin 150). Working Substrate was prepared by adding 4 ml of SUB A (citrate solution, 0.01% Hydrogen peroxide, 0.1% ProClin 150) to 1 ml of SUB B (0.1% 3,3´,5,5´-Tetramethylbenzidine (TMB), 40% Dimethylformamide (DMF)) and was mixed well.
Each strip was placed with the probe lines facing upward into the appropriate well of the 24-well tray. Then 4 ml of prewarmed Working Hybridization Buffer were added to each well. All wells contained a labeled strip. The tray was covered and placed in a 53 °c shaking water bath. The strips were hybridized for 30 minutes at a shaking speed of approximately 60 rpm. The tray was removed from the shaking water bath and the Working Hybridization Buffer was removed from the wells by vacuum aspiration. Then 4 ml of Working Ambient Wash Buffer was added to each strip, rinsed well 3 of 4 times and removed, after that Working Stringent Buffer was added to each well and the 24-well tray was placed again in the shaking water bath for 15 minutes. The Working Stringent Buffer was removed again by vacuum aspiration, the 24-well tray was removed from the 53 °c shaking water bath and placed at room temperature at a shaking speed of approximately 60 rpm for 30 minutes. Two washing procedures using 4 ml of Working Ambient Wash Buffer for 10 minutes each time were followed. Afterwards 4 ml of Working citrate buffer was added to each well for 5 minutes. At the last step 4 ml of Working Substrate was added to each well for 5 minutes. The strips were removed from the 24-well tray and placed on a clean non-porous surface and aligned according to the LINEAR ARRAY HPV Genotyping Test Reference Guide with the ink reference line at the top of the strip. For a valid run the β-globin bands must be visible.
Results and Discussion
The cervical smears were collected from Bulgarian patients with condylata acuminate lesions, in three hospitals in SofiaUniversity Hospital of Obstetrics and Gynaecology "Maichin Dom", "Tokuda" Hospital and the "National Institute of Oncology and Hematology". One hundred and twenty six cervicovaginal smears and scrapings were tested by this method. Forty two percent of them were found positive for HPV DNA and fifty eight percent, negative. We found more than one type of viral DNA in all positive samples. We found HPV 16 DNA in twenty two samples (38%); HPV 18 DNA, in eight samples (18%); HPV 6 DNA, in five cases (10%); HPV 53 DNA, in seven cases (11%); HPV 31 DNA, in three cases (4%); HPV 35, in four cases (5%), and in two cases we found viral DNA types HPV 61 and HPV 62. We found more then one type of viral DNA in all positive samples.
Roche's LINEAR ARRAY HPV method is based on PcR technology and type-specific hybridization with oligonucleotide probes. This method allows the detection of multiple infections and is very sensitive and well validated. It allows concomitant detection of 38 types and subtypes. The cervical smears were collected from patients with high-grade dysplasia. Our results showed prevalence of HPV 16 and HPV 18 types which are the most common high-risk types detected in patients with high-grade dysplasia or carcinoma in situ (1, 4, 7) . The other types which we detected are HPV 6 and HPV HPV 11-most common in patients with condilomata acuminate lesions; the other types which we found in these samples are classified as middle-and high-risk types (1, 4, 5) . The lack of viral DNA in some probe we could explain with the fact that some of the patients had been surgically treated and the tissues with the HPV infections had been removed. This study is still in progress and the results shown here are preliminarily. Further studies are needed to determine the influence these HPV infections have on the epidemiology of the genital tract of these patients.
Conclusions
Roche's LINEAR ARRAY HPV (CE-IVD) method can play an important role in further studies of the epidemiology of HPV infections because of its wide spectrum of HPV detection types and the easy way to visualize the PCR products without the need to use the toxic ethidium bromide.
